WACKER and CordenPharma Develop Solutions for Formulating Lipid Nanoparticles Expanding Their Portfolio for Advanced Medicines

Munich / Luxembourg, December 14, 2021 – WACKER and CordenPharma have signed a development partnership in the field of Lipid Nanoparticle formulation. The two companies announced today that they plan to jointly develop know-how and processes for the manufacturing of Lipid Nanoparticles (LNPs) to be used to meet the growing market demand. LNPs are drug delivery systems for nucleic acid therapeutics consisting of special fats, which ensure that actives can safely enter the body in order to exert their biological effect. The protective capsules are an essential component of advanced medicines such as mRNA-based drugs, protein replacement therapeutics, and antibody therapeutics.

För mer information se bifogad pressrelease.

For further information, please contact:

Wacker Chemie AG
Media Relations & Information
Manuela Dollinger
Tel. +49 89 6279-1629
manuela.dollinger@wacker.com
www.wacker.com

CordenPharma

Abby Thompson (North America) abby.thompson@cordenpharma.com
Eva Schaub (Europe & Asia) eva.schaub@cordenpharma.com